Astrazeneca (AZN) Free Cash Flow (2009 - 2026)

Astrazeneca's Free Cash Flow history runs 17 years deep, the most recent figure standing at $547.0 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 27.51% year-over-year to $547.0 million; the TTM figure through Mar 2026 stood at -$2.7 billion (down 40.79% YoY), while the FY2025 annual figure was $15.9 billion, up 13.76% from the prior year.
• Free Cash Flow was $547.0 million for Q1 2026 at Astrazeneca, up from -$4.6 billion in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $686.0 million in Q3 2025 to a low of -$4.6 billion in Q4 2025.
• Historically, Free Cash Flow has averaged -$246.0 million across 5 years, with a median of $382.0 million in 2024.
• Biggest YoY gain for Free Cash Flow was 72.51% in 2025; the steepest drop was 45.99% in 2025.
• A 5-year view of Free Cash Flow shows it stood at $253.0 million in 2022, then rose by 6.72% to $270.0 million in 2023, then plunged by 1262.96% to -$3.1 billion in 2024, then slumped by 45.99% to -$4.6 billion in 2025, then surged by 111.93% to $547.0 million in 2026.
• The last three Free Cash Flow figures came in at $547.0 million (Q1 2026), -$4.6 billion (Q4 2025), and $686.0 million (Q3 2025), per Business Quant data.